Influence of 131I therapy on parathyroid hormone in patients with differentiated thyroid cancer / 中华内分泌代谢杂志

ABSTRACT

Objective:This study aimed to investigate the influence of 131I therapy on parathyroid hormone (PTH) in differentiated thyroid cancer (DTC) patients. Methods:Clinical data were collected from 353 DTC patients (121 males and 232 females) with normal initial PTH (baseline PTH) and normal serum calcium who received 131I therapy, and tetany, limbs anesthesia, or paresthesia after the 131I therapy were also collected. Comparisons were performed on the changes of PTH, serum calcium, and serum phosphorus before and after 131I therapy. According to gender, age, histology, American Joint Committee on Cancer (AJCC) stages, administered activity, and residual thyroid tissue, further analyses were done for the difference of changes of PTH. Paired t-tests and Pearson χ 2 test were used to conduct statistics. Results:No patients suffered from tetany, limbs anesthesia, or paresthesia, etc. PTH showed a significant decrease [(39.83±16.94)μg/L vs (36.98±16.31)μg/L, P<0.01] after the 131I therapy. Serum calcium also decreased mildly [(2.30±0.12)mmol/L vs (2.27±0.14)mmol/L, P<0.01]. There was no significant difference in changes of PTH in gender, age, histology, AJCC stages, administered activity, and residual thyroid tissue. Conclusions:PTH of DTC patients decreased mildly after 131I therapy, and no hypocalcemia occurred. The change of PTH was not associated with sex, age, histology, AJCC stages, administered activity, and residual thyroid tissue.